Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Molecular Neuroimaging

Photo of Michael Schöll - Photographer: Johan Wingborg /GU

Principal Investigator: Michael Schöll

Our overall aim is to identify, using biomarkers derived from advanced imaging modalities such as positron emission tomography (PET) and magnetic resonance imaging (MRI) in combination with biomarkers based on the analysis of cerebrospinal fluid (CSF) or blood, the earliest neuropathogenic changes that differentiate a brain that will eventually develop a neurodegenerative disease such as Alzheimer’s disease from a brain that will age healthily.

The early identification of these processes using adequate biomarkers is of crucial importance not only to improve our understanding of the pathogenesis of neurodegenerative disorders but also to support reliable clinical diagnoses, the identification of at-risk individuals, and the evaluation of treatment outcome.

Our group also supports other researchers, predominantly within neurology and psychiatry, who aim to incorporate molecular imaging in their scientific work.

Our research group is part of the Wallenberg Centre for Molecular and Translational Medicine (WCMTM).

Read more about our research at the WCMTM web site >>>

Group members

Michael Schöll

Principal Investigator
michael.scholl@neuro.gu.se

Kerstin Heurling

Postdoctor
kerstin.heurling@gu.se  

 

Contact information

Michael Schöll

michael.scholl@neuro.gu.se

Department of Psychiatry and Neurochemistry
Su Sahlgrenska
41345 Göteborg

Visiting Addresses:
MedTech West
Röda Stråket 10B
413 45 Göteborg

Memory Clinic
Wallinsgatan 6
431 41 Mölndal
 

Page Manager: Josefin Bergenholtz|Last update: 5/8/2017
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?